BioVaxys Technology Corp. (CSE:BIOV)

BioVaxys Technology Balance Sheet

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Cash & Equivalents	0.21	0	0.14	0.59	2.42
Cash & Short-Term Investments	0.21	0	0.14	0.59	2.42
Cash Growth	21579.22%	-99.31%	-76.08%	-75.52%	958.21%
Other Receivables	0.44	0.09	0.05	0.05	0.05
Receivables	0.44	0.09	0.21	0.13	0.05
Prepaid Expenses	0.65	0.02	0.36	0.15	0.59
Total Current Assets	1.3	0.11	0.71	0.87	3.06
Other Intangible Assets	-	-	-	7.4	7.4
Total Assets	1.3	0.11	0.87	8.5	10.46
Accounts Payable	1.56	2.66	1.31	0.22	0.75
Accrued Expenses	1.6	0.83	0.33	0.11	0.15
Short-Term Debt	0.07	-	-	-	-
Total Current Liabilities	3.22	3.49	1.64	0.33	0.9
Total Liabilities	3.22	3.49	1.64	0.33	0.9
Common Stock	27.04	21.99	17.05	14.76	10.75
Retained Earnings	-31.25	-27.3	-19.61	-8.02	-1.56
Comprehensive Income & Other	2.29	1.93	1.78	1.44	0.37
Shareholders' Equity	-1.92	-3.37	-0.77	8.18	9.56
Total Liabilities & Equity	1.3	0.11	0.87	8.5	10.46
Total Debt	0.07	-	-	-	-
Net Cash (Debt)	0.14	0	0.14	0.59	2.42
Net Cash Growth	14610.95%	-99.31%	-76.08%	-75.52%	958.21%
Net Cash Per Share	0.00	0.00	0.00	0.01	0.09
Filing Date Shares Outstanding	291.53	220.24	115.25	99.66	81.53
Total Common Shares Outstanding	262.06	145.11	108.81	92.19	74.07
Working Capital	-1.92	-3.37	-0.92	0.55	2.16
Book Value Per Share	-0.01	-0.02	-0.01	0.09	0.13
Tangible Book Value	-1.92	-3.37	-0.77	0.78	2.16
Tangible Book Value Per Share	-0.01	-0.02	-0.01	0.01	0.03

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.